Rapport Therapeutics Inc.
RAPP
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.52B
Close$
$0.88
97.9% downside
Current Fair Value
97.9% downsideOvervalued by 97.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.52 Billion |
|---|---|
| Enterprise Value | $1.46 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.86 |
| Beta | 0.95 |
| Outstanding Shares | 47,236,618 |
Return
| Return on Equity | -22.75% |
|---|---|
| Return on Assets | -21.56% |
| Return on Invested Capital | -26.11% |
Valuation & Multiples
| P/E Ratio | -16.06 |
|---|---|
| PEG | 91.87 |
| Price to Sales | - |
| Price to Book Ratio | 4.61 |
| Enterprise Value to Revenue | 72.83 |
| Enterprise Value to EBIT | -11.63 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.62
Average shareholder expectationRevenue Estimate
$7.50 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.96
Average shareholder expectationRevenue Estimate
$2.22 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 56.76% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▼ 111.69% |
|---|---|
| Total Invested | $608,298▼ 99.96% |
| Investors Holding | 4▼ 144.00% |
ESG Score
No data